Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance.
Manuel Francisco Ugarte-GilGraciela S AlarconZara IzadiAli Duarte GarciaCristina Reatégui-SokolovaAnn Elaine ClarkeLeanna WiseGuillermo J Pons-EstelMaria Jose SantosSasha BernatskySandra Lucia Euzébio RibeiroSamar Al EmadiJeffrey A SparksTiffany Y-T HsuNaomi J PatelEmily L GilbertMaria O Valenzuela-AlmadaAndreas JönsenGianpiero LandolfiMicaela FrediTiphaine GoulenokMathilde DevauxXavier MarietteViviane QueyrelVasco C RomãoGraca SequeiraRebecca HasseliBimba HoyerReinhard E VollChristof SpeckerRoberto BaezVanessa Castro-CoelloHernan Maldonado FiccoEdgard Torres Dos Reis-NetoGilda Aparecida Aparecida FerreiraOdirlei Andre André MonticieloEmily SirotichJean LiewJonathan S HausmannPaul SufkaRebecca GraingerSuleman BhanaWendy CostelloZachary S WallaceLindsay JacobsohnTiffany TaylorClairissa JaAnja StrangfeldElsa F MateusKimmie L HyrichLoreto CarmonaSaskia Lawson-ToveyLianne Kearsley-FleetMartin SchaeferPedro M MachadoPhilip C RobinsonMilena GianfrancescoJinoos YazdanyPublished in: Annals of the rheumatic diseases (2022)
More severe COVID-19 outcomes in individuals with SLE are largely driven by demographic factors, comorbidities and untreated or active SLE. Patients using glucocorticoids also experienced more severe outcomes.